Get the latest news, insights, and market updates on PRPH (ProPhase Labs, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
ProPhase Labs to Present at the 2025 ThinkEquity Conference
UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies Oct 24, 2025 - $PRPH
ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology
Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating Potential UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, th Oct 22, 2025 - $PRPH
PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE
COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, advancing the Crown Medical Collections initiative to the key next step. T Sep 23, 2025 - $PRPH
ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, together with BE-Smart’s demonstrated compatibility with both brush and forceps biopsies, supports earlier detection. UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (the “Company” or “ProPhase”) today announced that the Aug 12, 2025 - $PRPH
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investo Aug 11, 2025 - $PRPH
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple